Immunogenicity of two doses of inactive COVID‐19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

We aimed to evaluate the seroconversion rates after two doses of inactive COVID‐19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. Patients with solid tumors receiving active treatment (n = 101) and patients with no‐cancer...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2023-02, Vol.152 (4), p.679-685
Main Authors: Guven, Deniz Can, Incesu, Fatma Gul Gulbahce, Yildirim, Hasan Cagri, Erul, Enes, Chalabiyev, Elvin, Aktas, Burak Yasin, Yuce, Deniz, Arik, Zafer, Kilickap, Saadettin, Aksoy, Sercan, Erman, Mustafa, Hayran, Kadir Mutlu, Unal, Serhat, Alp, Alpaslan, Dizdar, Omer
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Viral
BNT162 Vaccine
Cancer
Cancer Epidemiology
Cancer therapies
Cancer vaccines
Chemotherapy
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Enzyme-linked immunosorbent assay
Humans
Immunogenicity
Immunoglobulin G
Immunotherapy
Medical research
mRNA
mRNA Vaccines
Neoplasms - therapy
RNA, Messenger - genetics
Seroconversion
Severe acute respiratory syndrome coronavirus 2
Solid tumors
Vaccination
vaccine response
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate the seroconversion rates after two doses of inactive COVID‐19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. Patients with solid tumors receiving active treatment (n = 101) and patients with no‐cancer (n = 48) as the control group were included in the study. All the patients and controls had received two doses of CoronaVac and a third booster dose of the mRNA vaccine (Bnt162b2). Anti‐SARS‐CoV‐2 Spike Receptor Binding Domain IgG antibody levels after the second and third dose were measured with quantitative ELISA. The median age of the patients was 66 (IQR 60‐71). 79% of the patients were receiving chemotherapy, and 21% were receiving immunotherapy at the time of vaccination. Antibody levels measured after two doses of CoronaVac were significantly lower in patients with cancer than in the control group (median 0 μg/ml [IQR 0‐1.17 μg/ml] vs median 0.91 μg/ml [IQR 0‐2.24 μg/ml], respectively, P = .002). Seropositivity rates were 46.5% in patients with cancer and 72.9% in the control group (P = .002). Antibody measurement was performed in 26 patients after the third dose. Seroconversion rate increased from 46.5% to 88.5% (P 
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.34280